IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
In this conference session, Dr. Ruben Mesa, MD discusses the different features between MDS and MPN and their overlap syndromes.
In this conference session, Dr. Krisstina Gowin DO discusses best practices when living with
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders,
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.
Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease metastasized and took the man’s life.
Stone says he went from being middle class to poor rapidly after his father died. “And that sort of gave me the incentive to work hard,” he said.
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
